- Home
- PETS vs IFRX Comparison
PETS vs IFRX Comparison
Compare PETS & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | IFRX |
|---|---|---|
| Founded | 1996 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.8M | 86.0M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | PETS | IFRX |
|---|---|---|
| Price | $1.65 | $1.09 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $3.20 | ★ $8.50 |
| AVG Volume (30 Days) | 225.0K | ★ 7.7M |
| Earning Date | 02-02-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $226,972,000.00 | $73,729.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.98 | $1,075.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.59 | $0.71 |
| 52 Week High | $6.85 | $2.82 |
Technical Indicators
Market Signals| Indicator | PETS | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 32.70 | 42.21 |
| Support Level | $1.69 | $0.92 |
| Resistance Level | $1.83 | $1.28 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 13.04 | 30.42 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.